vs
Amneal Pharmaceuticals, Inc.（AMRX）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是Amneal Pharmaceuticals, Inc.的1.4倍（$1.1B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -127.8%，领先132.1%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs -2.5%），百利高自由现金流更多（$148.6M vs $108.5M），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 1.3%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
AMRX vs PRGO — 直观对比
营收规模更大
PRGO
是对方的1.4倍
$814.3M
营收增速更快
AMRX
高出14.0%
-2.5%
净利率更高
AMRX
高出132.1%
-127.8%
自由现金流更多
PRGO
多$40.1M
$108.5M
两年增速更快
AMRX
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.1B |
| 净利润 | $35.1M | $-1.4B |
| 毛利率 | 36.5% | 32.6% |
| 营业利润率 | 13.8% | -116.0% |
| 净利率 | 4.3% | -127.8% |
| 营收同比 | 11.5% | -2.5% |
| 净利润同比 | 212.9% | -3093.9% |
| 每股收益（稀释后） | $0.10 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXPRGO
| Q4 25 | $814.3M | $1.1B | ||
| Q3 25 | $784.5M | $1.0B | ||
| Q2 25 | $724.5M | $1.1B | ||
| Q1 25 | $695.4M | $1.0B | ||
| Q4 24 | $730.5M | $1.1B | ||
| Q3 24 | $702.5M | $1.1B | ||
| Q2 24 | $701.8M | $1.1B | ||
| Q1 24 | $659.2M | $1.1B |
净利润AMRXPRGO
| Q4 25 | $35.1M | $-1.4B | ||
| Q3 25 | $2.4M | $7.5M | ||
| Q2 25 | $22.4M | $-8.4M | ||
| Q1 25 | $12.2M | $-6.4M | ||
| Q4 24 | $-31.1M | $-44.4M | ||
| Q3 24 | $-156.0K | $-21.0M | ||
| Q2 24 | $6.0M | $-108.4M | ||
| Q1 24 | $-91.6M | $2.0M |
毛利率AMRXPRGO
| Q4 25 | 36.5% | 32.6% | ||
| Q3 25 | 34.9% | 36.1% | ||
| Q2 25 | 39.5% | 34.4% | ||
| Q1 25 | 36.8% | 37.6% | ||
| Q4 24 | 36.0% | 33.9% | ||
| Q3 24 | 38.4% | 37.2% | ||
| Q2 24 | 35.6% | 37.0% | ||
| Q1 24 | 36.1% | 33.1% |
营业利润率AMRXPRGO
| Q4 25 | 13.8% | -116.0% | ||
| Q3 25 | 9.0% | 7.0% | ||
| Q2 25 | 15.4% | 4.3% | ||
| Q1 25 | 14.4% | 4.5% | ||
| Q4 24 | 10.4% | 10.0% | ||
| Q3 24 | 12.6% | 7.4% | ||
| Q2 24 | 13.6% | -2.5% | ||
| Q1 24 | -1.6% | -5.1% |
净利率AMRXPRGO
| Q4 25 | 4.3% | -127.8% | ||
| Q3 25 | 0.3% | 0.7% | ||
| Q2 25 | 3.1% | -0.8% | ||
| Q1 25 | 1.8% | -0.6% | ||
| Q4 24 | -4.3% | -3.9% | ||
| Q3 24 | -0.0% | -1.9% | ||
| Q2 24 | 0.9% | -10.2% | ||
| Q1 24 | -13.9% | 0.2% |
每股收益（稀释后）AMRXPRGO
| Q4 25 | $0.10 | $-10.23 | ||
| Q3 25 | $0.01 | $0.05 | ||
| Q2 25 | $0.07 | $-0.06 | ||
| Q1 25 | $0.04 | $-0.05 | ||
| Q4 24 | $-0.10 | $-0.32 | ||
| Q3 24 | $0.00 | $-0.15 | ||
| Q2 24 | $0.02 | $-0.79 | ||
| Q1 24 | $-0.30 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | — |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $2.9B |
| 总资产 | $3.7B | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXPRGO
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | $432.1M | ||
| Q2 25 | $71.5M | $454.2M | ||
| Q1 25 | $59.2M | $409.9M | ||
| Q4 24 | $110.6M | $558.8M | ||
| Q3 24 | $74.0M | $1.5B | ||
| Q2 24 | $43.8M | $542.8M | ||
| Q1 24 | $46.5M | $658.5M |
总债务AMRXPRGO
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXPRGO
| Q4 25 | $-70.8M | $2.9B | ||
| Q3 25 | $-109.5M | $4.4B | ||
| Q2 25 | $-112.1M | $4.5B | ||
| Q1 25 | $-131.7M | $4.4B | ||
| Q4 24 | $-109.3M | $4.3B | ||
| Q3 24 | $-93.4M | $4.6B | ||
| Q2 24 | $-57.5M | $4.5B | ||
| Q1 24 | $-63.7M | $4.7B |
总资产AMRXPRGO
| Q4 25 | $3.7B | $8.5B | ||
| Q3 25 | $3.6B | $10.1B | ||
| Q2 25 | $3.4B | $10.1B | ||
| Q1 25 | $3.4B | $9.8B | ||
| Q4 24 | $3.5B | $9.6B | ||
| Q3 24 | $3.5B | $11.2B | ||
| Q2 24 | $3.5B | $10.4B | ||
| Q1 24 | $3.5B | $10.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $148.6M |
| 自由现金流率自由现金流/营收 | 13.3% | 13.4% |
| 资本支出强度资本支出/营收 | 2.7% | 2.4% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $145.1M |
8季度趋势，按日历期对齐
经营现金流AMRXPRGO
| Q4 25 | $130.3M | $175.4M | ||
| Q3 25 | $118.5M | $51.7M | ||
| Q2 25 | $83.8M | $75.9M | ||
| Q1 25 | $7.4M | $-64.5M | ||
| Q4 24 | $118.1M | $312.6M | ||
| Q3 24 | $141.8M | $42.2M | ||
| Q2 24 | $39.7M | $9.5M | ||
| Q1 24 | $-4.4M | $-1.4M |
自由现金流AMRXPRGO
| Q4 25 | $108.5M | $148.6M | ||
| Q3 25 | $106.2M | $29.8M | ||
| Q2 25 | $61.0M | $56.7M | ||
| Q1 25 | $-5.8M | $-90.0M | ||
| Q4 24 | $102.9M | $274.9M | ||
| Q3 24 | $124.8M | $15.1M | ||
| Q2 24 | $29.0M | $-18.9M | ||
| Q1 24 | $-13.6M | $-26.5M |
自由现金流率AMRXPRGO
| Q4 25 | 13.3% | 13.4% | ||
| Q3 25 | 13.5% | 2.9% | ||
| Q2 25 | 8.4% | 5.4% | ||
| Q1 25 | -0.8% | -8.6% | ||
| Q4 24 | 14.1% | 24.2% | ||
| Q3 24 | 17.8% | 1.4% | ||
| Q2 24 | 4.1% | -1.8% | ||
| Q1 24 | -2.1% | -2.4% |
资本支出强度AMRXPRGO
| Q4 25 | 2.7% | 2.4% | ||
| Q3 25 | 1.6% | 2.1% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 1.9% | 2.4% | ||
| Q4 24 | 2.1% | 3.3% | ||
| Q3 24 | 2.4% | 2.5% | ||
| Q2 24 | 1.5% | 2.7% | ||
| Q1 24 | 1.4% | 2.3% |
现金转化率AMRXPRGO
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | 6.89× | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
